Navigation Links
Digit in Biological Technology

Caliper Life Sciences Reports Second Quarter 2009 Results

...under the heading "Reconciliation of GAAP to Non-GAAP Financial Measures." "IVIS((R)) imaging and LabChip((R)) products delivered strong double digit organic growth, while overall growth was dampened by lower Automation and CDAS revenues," commented Kevin Hrusovsky, Caliper's president and CEO. "De...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

... edge products. 2009 OUTLOOK: Management reaffirmed its full year 2009 organic sales growth expectation in a low single digit range. This sales growth is expected to result from new product launches and other global sales initiatives. Demand for Sigma-Aldrich's products, pa...

Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09

...ased capacity for continued growth TORONTO, May 14 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) announced today robust double digit growth in sales, improved cash flow, and reduced operating losses for the second quarter ended March 31, 2009. In a news release today, William J. G...

Shire begins the year with a strong performance

...SRENOL(R) (lanthanum carbonate) was launched in Japan through Shire's partner Bayer Yakuhin Limited ("Bayer"). Shire will receive a double digit royalty on Bayer's net sales of FOSRENOL, which will be recorded by Shire as royalty income within revenues. License agreement for LIALDA ...

Beckman Coulter Announces First Quarter 2009 Results

...tates decreased 3%, due to a 25% decline in cash instrument sales. In constant currency, international revenue grew 2.7%, on the strength of a double digit increase in Clinical Diagnostics recurring revenue driven by mid-teens growth within Access Immunoassay. In the quarter, the company reclassifi...

BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma

...ith metastatic disease are directly enrolled into a clinical trial. The vast majority of experimental therapies have failed to show more than a single digit response rate. About BioVex BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch g...

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results

...up to $50 million upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and escalating double digit royalties on future net sales of products. Galderma will be responsible for the development costs of the acne and other indications, except in Japan,...

International Isotopes Inc. Announces Year End Financial Results

...ucts reflected a small 2% growth in 2008, that segment remains a major area of importance to the Company and one that we hope will re-establish double digit growth in 2009. Most significant perhaps is the 34% increase in gross profit for the year compared to 2007. That increase reflects strong improvemen...

NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

... - Up to $50 Million Potential Milestones plus Double digit Royalties on Future Sales - - Company to Host Conference Call at 11:00 a.m. ET Today - EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/...

ThromboGenics Announces Business Update and 2008 Full Year Results

...d BioInvent shared 60/40, an upfront payment of EUR50 million and could potentially share up to EUR450 million in milestone payments as well as double digit royalties on the same basis. TB-403 is being developed as an anti-cancer agent, and is currently in a Phase Ib clinical trial. TB-403 acts selectively...

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

...7 caused no significant impairment of attention, vigilance, information processing or declarative memory as measured by the Leeds Psychomotor Battery, digit Symbol Substitution Test or Word Pair Associates Test. Pharmacokinetic analyses revealed dose-related increases in exposure to ITI-007 and two metabo...

Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.

... decline in 2009, but with new program launches, global sales initiatives and market share gains, the Company expects to be able to achieve low single digit organic sales growth in 2009. Currency is expected to reduce otherwise reportable growth in 2009 by approximately 7% if exchange rates remain at curre...

Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results

...s remain solid," said Joe Kaufmann, President and CEO of the Company. "For the second consecutive quarter, we have achieved record earnings and double digit increases in our biomaterial sales and orthopaedic royalties. Our balance sheet continued to strengthen by generating $4.7 million in operating cash ...

Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend

...13% for 2008, and expects to continue the positive trend in 2009. The company's report stands in contrast to analyst estimates of flat to low single digit growth for the U.S. IT services industry overall, as the economic downturn affects IT services spending across most industries. "Our success in t...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

...omet would be eligible for an option exercise fee and milestone payments of up to Euro 290 million (approx. US$ 390 million) in total and up to double digit royalties based on tiered net sales of the product. In addition, Micromet would be reimbursed for its R&D expenses incurred in connection with th...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

...lling, and administrative expenses are projected to show flat to low-single digit growth while research and development expenses are projected to grow in the...are expected to grow more slowly than sales, registering flat to low-single digit growth. Other income is expected to contribute less than $75 millio...

CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market

...igence company, the biofuel market is estimated at 33 billion with a double digit annual growth. The market consists of approximately 85% bioethanol and 15% ...igence company, the biofuel market is estimated at 33 billion with a double digit annual growth. The market consists of approximately 85% bioethanol and 15% ...

Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award

...arketing initiatives, making extensive use of various media and consumer outreach strategies to promote its brand, life'sDHA . This has led to double digit growth in consumer awareness of the life'sDHA brand since the brand was launched in 2006. As a result, Martek is one of the few companies providing ...

CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market

...igence company, the biofuel market is estimated at 33 billion with a double digit annual growth. The market consists of approximately 85% bioethanol and 15% ...igence company, the biofuel market is estimated at 33 billion with a double digit annual growth. The market consists of approximately 85% bioethanol and 15% ...

William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market

...he US Marketing Director on November 10th, 2008. Gary Zamler, Simbionix CEO stated, "Over the past two consecutive years, Simbionix has enjoyed double digit revenue growth in both our International and Domestic markets. We are particularly pleased to have someone of Bill's caliber join our expanding US org...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... and equity. Cellzome is eligible for up to GBP118 million per program in potential development, regulatory and commercial milestones and up to double digit royalties on net sales of products resulting from the alliance. Jose Carlos Gutierrez-Ramos, Ph.D, Senior Vice President and Head of the Immuno-Infl...

BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease

...previously announced that its third party royalty obligations for Dupuytren's disease are 0.5% of net sales. Auxilium is obligated to pay low double digit royalties at a flat rate as a percentage of future worldwide net sales for all clinical indications, irrespective of territory, and independent of sal...

ThromboGenics Announces Half Year Results 2008

... and BioInvent received an upfront payment of EUR50 million and could potentially share up to EUR450 million in milestone payments as well as double digit royalties. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the developm...

Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America

...he terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon commercialization of MuGard. Milestone expects to launch MuGard in the US early in the first quarter of 2009. "We are pleased to have M...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...odels and in human trials. Under the terms of the agreement ASK will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization of ProLindac. In addition, in co-operation with Access, ASK has committed to fund and execute two (2) Phase 2 studies f...

China Medicine Announces Solid First Quarter 2008 Results

...ased 49.5% from Q1 of 2007, to $1.4 million -- Net income increased 54.0% from Q1 of 2007, to $1.2 million "During the first quarter, we saw double digit growth in our pharmaceutical product sales compared to the same quarter last year," said Mr. Senshan Yang, Chairman and CEO of the Company. "We are ve...

Pharsight Achieves $7.6 Million In Quarterly Revenue

...28.3 million, up 13% from $25.1 million for 2007. "We finished fiscal 2008 and enter fiscal 2009 very confident about our ability to generate double digit growth at both the top and bottom line," said Shawn O'Connor, chairman and chief executive officer of Pharsight. "Our team is doing an excellent job o...

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

...sales of HPV products, stemming from Transgene's research. Under the terms of the agreement, Transgene is also entitled to receive progressive, double digit royalties on all future sales. Strengthening of the Equity Base: In July 2007, the company raised EUR100.1m (EUR96.4m net of costs) from European eq...

Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results

... November 2007, which increased capacity for polyclonal antibody production by 44%. -- SDI reported the sixth consecutive quarter of double digit year-over-year growth in the antibody business. -- SDI reported the third consecutive quarter of more than 20% year-over-year growth in the f...

Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation

...ximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates. Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-...

Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results

...de significant strides in positioning the Company for consistent future growth. Sales in all of the markets in which we compete achieved strong double digit growth. We are very pleased with the continued market acceptance of our dental products, the strong increase in overall domestic sales and the strong ...

Carrington Reports Third Quarter 2007 Results

... - Revenues Down from Same Quarter Last Year - Second Consecutive Double digit Quarter-to-Quarter Revenue Gain - DelSite Continues Toward Phase I Vaccine Clinical Trial IRVING, Texas, Nov. 27 /PRNewswire-FirstCall/ -- Car...

GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry

... and $331 million for each product candidate. If GlaxoSmithKline exercises its option at the proof of concept stage, Anacor will receive tiered double digit royalties, which are dependent on sales achieved. Boron has been a relatively underutilized element in pharmaceutical products, in part due to a lack...

Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201

...th dose levels, on the subjective perception of sleep quality. The following morning there was no subjective perception of any residual sedation. The digit Symbol Substitution Test (DSST) showed a small but clinically insignificant change tested the next day 9 h after dosing. The PSG analysis also showed...

Confoti: Revisiting a dotcom business model

...rs can use their mobile phones as a music recognition device. . . Finally, digit Wireless, makers of the Fastap keypad, closed $4.3 million in its second r... of funding. Included in this round were QUALCOMM Inc. and TELUS Ventures. digit Wireless hopes to use the funds to continue its global expansion in the U...

Tech Digest: what's moving in the Midwest

...st Dominik Scheible of Ludwig-Maximilians University in Munich have applied for a patent on a device that uses just one electron to represent a binary digit a 1 or a 0. Unlike previous one-electron transistors, theirs does not need to be super-cooled to work. The more electrons are used for each bit of...

Biotech flourishes in 2005 while Big Pharma is on the decline

...unexciting. Four of the top ten companies had negative performances, with another company showing no growth. Another four companies showed only single digit growth. In general, Big Pharma is still in trouble as a number of their blockbuster drugs come off in patent in the next few years and with few pot...

Will BidRx start a drug price war?

...ars - and companies may not have been interested in an alternative to the employer-based insurance model until drug costs started increasing at double digit annual rates. ...

CEO of healthcare group still hopeful IT will save employers money

...eds to do in order to address costs, but there are so many other factors." Paying the price In recent years, those factors have sparked double digit premium increases, which in turn have prompted employers to ask workers to contribute more for their health insurance in the form of higher co-pays. A...
Other Tags
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
(Date:9/19/2014)... 2014 The Alliance for Bangladesh ... the National Fire Protection Association (NFPA), a recognized ... today in a Memorandum of Understanding signed by ... and other stakeholders with information, guidance and access ... health and safety of workers in ready-made garment ...
Breaking Medicine News(10 mins):Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
Other Contents